Published in Onco Targets Ther on October 25, 2016
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Epigenetics in human disease and prospects for epigenetic therapy. Nature (2004) 11.46
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med (2010) 5.54
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 4.22
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol (2014) 3.64
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J Clin Invest (1980) 2.80
Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem (2000) 2.53
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut (2013) 2.17
Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology (1989) 2.03
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem (2014) 1.78
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol (2006) 1.69
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
Methylation of endogenous human retroelements in health and disease. Curr Top Microbiol Immunol (2006) 1.65
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (1983) 1.57
K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol (1999) 1.53
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. Clin Chem (2015) 1.45
Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion (2001) 1.43
Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res (2000) 1.40
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer (2006) 1.32
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol (2014) 1.31
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res (2015) 1.29
Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol (2014) 1.28
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
The epigenetic promise for prostate cancer diagnosis. Prostate (2011) 1.26
Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One (2011) 1.21
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA. Clin Chem (2015) 1.20
Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem (2003) 1.19
Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer (2011) 1.19
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J Thorac Oncol (2011) 1.17
Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS One (2012) 1.14
Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer (2011) 1.07
Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci (2008) 1.05
Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04
Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem (2005) 1.04
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res (2015) 1.03
Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. Eur Urol (2016) 1.03
Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer (2014) 1.03
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol (2010) 1.03
Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci (2008) 1.03
Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn (2008) 1.02
Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol (2014) 1.01
A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas (2002) 1.00
DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer (2011) 0.99
Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer (2011) 0.99
Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One (2015) 0.98
Medicine. Keeping tabs on tumor DNA. Science (2010) 0.98
Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol (2009) 0.97
Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Ann N Y Acad Sci (2004) 0.96
Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol (2007) 0.94
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease. Br J Cancer (2015) 0.92
A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clin Cancer Res (2016) 0.92
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res Treat (2014) 0.91
Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. Oncol Rep (2007) 0.89
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol (2012) 0.88
Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Cancer Epidemiol (2013) 0.88
Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res (2014) 0.88
Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2007) 0.88
Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep (2014) 0.88
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res (2007) 0.87
Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. Biomed Res Int (2013) 0.87
DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res (2006) 0.86
Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark (2005) 0.86
Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers (2009) 0.84
Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers (2007) 0.84
Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J Mol Diagn (2012) 0.84
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. Eur J Hum Genet (2016) 0.84
Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol (2015) 0.84
Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Transl Oncol (2015) 0.83
Usefulness of plasma epigenetic changes of five major genes involved in the pathogenesis of colorectal cancer. Int J Colorectal Dis (2012) 0.83
Circulating tumor DNA: new horizons for improving cancer treatment. Future Oncol (2015) 0.83
DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol (2011) 0.82
Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol (2014) 0.80
Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. Dis Markers (2015) 0.80
Detection of serum Alu element hypomethylation for the diagnosis and prognosis of glioma. J Mol Neurosci (2013) 0.79
Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.79
Assessment of DNA Integrity, Applications for Cancer Research. Adv Clin Chem (2015) 0.79
Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential. Expert Rev Anticancer Ther (2012) 0.78
Preliminary study analyzing the methylated genes in the plasma of patients with pancreatic cancer. Scand J Surg (2012) 0.78
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Semin Radiat Oncol (2015) 0.77
Microsatellite instability typing in serum and tissue of patients with colorectal cancer: comparing real time PCR with hybridization probe and high-performance liquid chromatography. Mol Biol Rep (2014) 0.77
Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA. Cancer Biomark (2014) 0.76
Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis. Clin Lab (2014) 0.76
Quantitative analysis of cell-free DNA in ovarian cancer. Oncol Lett (2015) 0.76
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget (2016) 0.76
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer (2014) 1.00
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget (2016) 0.93
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget (2016) 0.84
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. Oncotarget (2016) 0.80
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clin Genitourin Cancer (2016) 0.76
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urol Oncol (2017) 0.75
Reduction of (68)Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging (2017) 0.75